Barclays Cuts Avidity Biosciences (NASDAQ:RNA) Price Target to $57.00
Avidity Biosciences (NASDAQ:RNA – Free Report) had its target price cut by Barclays from $63.00 to $57.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the stock. Needham & Company LLC reissued […]
Avidity Biosciences (NASDAQ:RNA – Free Report) had its target price cut by Barclays from $63.00 to $57.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the stock. Needham & Company LLC reissued […]
